Readiness to Implement Novel SACT: Tumor-Infiltrating Lymphocyte Therapy

Area of Science:

• Oncology
• Cell Therapy
• Immunotherapy

Background:

• Adoptive cell therapy, specifically tumor-infiltrating lymphocyte (TIL) therapy, demonstrates significant potential for treating solid tumors.
• Clinical trials indicate promising results, necessitating preparation for increased trial volume and patient access.

Purpose of the Study:

• To provide guidance on the essential role of nurses in the delivery of tumor-infiltrating lymphocyte (TIL) therapy.
• To address the identified knowledge gaps and organizational readiness challenges for adoptive cell therapy.

Main Methods:

• Guidance developed from a review of peer-reviewed literature and best practice guidelines (2006-2024).
• Literature search conducted using PubMed, CINAHL, and MEDLINE databases.
• Incorporation of expert experience in managing patients undergoing TIL therapy in clinical trials.

Main Results:

• TIL therapy has the potential to revolutionize care pathways by inducing durable tumor responses.
• Successful implementation faces challenges, emphasizing the central role of nurses in coordinating safe delivery and patient care.
• Nurses require comprehensive knowledge of regulatory processes, treatment pathways, side effect management, and patient expectations.

Conclusions:

• Safe delivery of TIL therapy necessitates a specialist team and robust coordination across all stages, from referral to administration.
• Organizations must assess infrastructure, address skill gaps, and ensure high-level training for all involved healthcare professionals.
• Establishing strong governance structures is crucial for the successful integration of TIL therapy into clinical practice.